Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Data-driven characterization of distinct cognitive subtypes in Parkinson's disease dementia

  • Labrador-Espinosa, Miguel
  • Silva-Rodríguez, Jesús
  • Mir, Pablo
  • Grothe, Michel J.
Data used in the preparation of this study were obtained from the Parkinson’s Progression Markers Initiative database, which is publicly available to interested researchers (www.ppmi-info.org)., Individual cognitive profiles of patients with Parkinson's disease dementia (PDD) are highly heterogeneous, suggesting possible biological subtypes. We studied 75 PD patients who developed dementia in the course of the Parkinson's Progression Markers Initiative study to investigate data-driven evidence for the existence of distinct cognitive subtypes of PDD. Using Ward's hierarchical clustering on neuropsychological test data, we identified two distinct cognitive subtypes. Despite similar dementia severity (MoCA: 20.6 vs 20.0), cluster-A exhibited more pronounced memory deficits (n = 50), whereas cluster-B showed greater visuospatial impairments (n = 25). The subtypes did not differ in demographic, motor, or MRI-based neurodegeneration measures. However, the visuospatial-predominant cluster-B had a higher prevalence of GBA mutations (p = 0.003) and hallucinations (p = 0.009). No differences were found in APOE-ε4 prevalence or cerebrospinal fluid biomarkers of Alzheimer's pathology. These findings reveal distinct memory-predominant and visuospatial-predominant PDD subtypes, which associate with different clinical and genetic features but are independent of comorbid Alzheimer's pathology., Data used in the preparation of this manuscript were obtained from the Parkinson’s Progression Markers Initiative database (www.ppmi-info.org/data). For up-to-date information on the study visit www.ppmi-info.org. Parkinson’s Progression Markers Initiative—a public-private partnership—is funded by The Michael J. Fox Foundation for Parkinson’s Research. Corporate funding partners include AbbVie, Allergan, Amathus, Avid, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, GE Healthcare, Genentech, GlaxoSmithKline, Janssen Neurosciene, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Prevail, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager, and the philanthropic funding partner is Golub Capital. This work was supported by research grants from the Spanish Ministry of Science, Innovation and Universities (CNS2024-154295; RYC2023-043746-I), the Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional (ISCIII-FEDER: PI22/01704; PI24/00089; CP19/00031), and the Reina Sofia Foundation (E.6.4 FRS-CUERPOS DE LEWY)., Peer reviewed